
●

Table of Ambition and Progress Towards the Sustainable Development Goals (SDGs)

●

EXECUTIVE SUMMARY

Today we are confronted by societal challenges like a growing and aging population, income disparities and climate change. At the same time, technological advances (such as the rise of digitization) present significant opportunities as well as challenges. Given these profound upheavals, companies are not only required to perform well financially, but must also explain what they are doing to respond to those challenges and demonstrate that they are making a positive contribution to society.

Sanofi's primary contribution is to serve patients' needs throughout their health journeys, whether they be someone with a rare disease or one of the millions of men and women living with a chronic illness. It also includes providing vaccine protection to populations, as well as pain relief treatments.

In this respect we contribute to Sustainable Development Goal 3: "Ensure healthy lives and promote well-being for all at all ages", in particular SDG 3.3 on communicable diseases through our vaccine portfolio and SDG 3.4 on non-communicable diseases through our treatments for diabetes, cardiovascular diseases and rare diseases. Details about our programs on access to healthcare are provided in our [2022 Declaration of Extra-Financial Performance](#) (URD) – this document is also referenced below.

Sanofi initiatives that contribute to SDGs are shown in the table below.

Table of Sanofi’s Ambition and Progress Towards the Sustainable Development Goals (SDGs)

		Progress			
Topic	Ambition	2022	2021	Contribution to SDGs	
Access to Healthcare					
Sanofi Global Health	Make affordable 30 essential medicines to treat cardiovascular diseases, diabetes, tuberculosis, malaria, certain neglected tropical diseases, and cancer in the 40 countries with the lowest per capita GDP Help establish and enhance sustainable healthcare systems for people with chronic diseases that require long term care	See section “4.3.2., Access to healthcare” of the URD .	See section “4.2.2., Access to healthcare” of the URD .	SDG 3: Good health and well-being 	SDG 3.3: By 2030, end the Aids epidemic, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, waterborne diseases and other communicable diseases SDG 3.4: By 2030, reduce by one third premature mortality from noncommunicable diseases through prevention and treatment and promote mental health and well-being
Infectious diseases	To help eradicate sleeping sickness by 2030 To help eradicate polio	See section “4.3.2., Access to healthcare” of the URD .	See section “4.3.2., Access to healthcare” of the URD .		SDG 3.3
Non-communicable diseases	To help reduce the burden on low- and intermediate-income countries of non-communicable diseases like childhood cancer, diabetes and mental health disorders Donate 100,000 vials a year to treat people with rare diseases, via the Humanitarian Program launched by Sanofi Specialty Care	See section “4.3.2., Access to healthcare” of the URD .	See section “4.3.2., Access to healthcare” of the URD .		SDG 3.4

Human Capital					
Gender balance	Achieve gender balance in Sanofi Senior Leaders by 2025	41.7 %	40.1%	SDG 5: Gender equality 	SDG 5.5: Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision-making in political, economic and public life
	Achieve 40% of women in executive posts by 2025	37.2 %	34.2%		
Corporate Citizenship					
Decent work	Reduce the total occupational injury frequency rate (FR) – any employee(a) to below 2 by 2022 Reduce the lost time injury frequency rate – any employee (a) to below 1.4 by 2022	Total occupational injury FR – any employee: 2 Lost time injury FR – any employee: 1.3	Total occupational injury FR – any employee: 2 Lost time injury FR – any employee: 1.3	SDG 8: Decent work and economic growth 	SDG 8.8: Protect labor rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants and those in precarious employment
Communities	In France, reach 10% of work/study placements occupied by young people from deprived urban areas	9.7 %	8.5%	SDG 4: Quality education 	SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all
Planet Care					
Climate change - Carbon footprint (CO2 emissions)	Industrial, R&D and tertiary sites for Scopes 1 & 2 (including medical rep fleet): 55% reduction in greenhouse gas emissions (CO2 equivalent) by 2030 (relative to 2019) Carbon neutrality by 2030 and net zero emissions by 2045 (Scopes 1, 2 & 3)	(29.0) %	(24.0) %	SDG 13: Climate action 	SDG 13: Take urgent action to combat climate change and its impacts
Water	Industrial, R&D and tertiary sites - Quantitative objective: 15% reduction in water withdrawals by 2030 (relative to 2019)	(13) %	(13) %	SDG 6: Clean water and sanitation 	SDG 6.4: By 2030, considerably increase rational use of water resources in all

	Qualitative objective: implementation of efficient water management plans : - By 2025 for 100% of our priority sites - By 2030 for all our sites	See section "4.3.10.3.1., Water resource management plan" of the URD .	See section "4.2.10.3.1., Water resource management plan" of the URD .		sectors, and guarantee the viability of all withdrawals and supplies of fresh water so as to take account of water scarcity and sharply reduce the number of people suffering from water shortages
Waste	Reuse/recycle/recover at least 90% of our waste by 2025	86%	84%		SDG 12: Responsible production and consumption SDG 12.4: By 2020, achieve environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment SDG 12.5: By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse
	Achieve landfill disposal rate of below 1% of total waste by 2025	5 %	7%		
Sustainable management of products	All new products to be eco-designed by 2025 No vaccines supplied in blister packs by 2027	See section 4.3.10.5. "Eco-design" of the URD .	See section 4.2.10.4.3., "Ecodesign" of the URD .		
Pharmaceutical products in the environment	Monitor, control and reduce emissions on all production sites by 2025	100% of priority sites, 72% of production sites	100% of priority sites		SDG 6.3: By 2030, improve water quality by reducing pollution, eliminating dumping of waste at sea, reducing emissions of chemicals and hazardous materials to a minimum, reducing by half the proportion of untreated waste water, and significantly scale up recycling and reuse globally with no threat to water

<p>Biodiversity</p>	<p>Biodiversity protection programs at all priority sites located close to sensitive natural spaces by 2025; 100% of sites operating at least one initiative.</p>	<p>48% of sites have implemented at least one initiative</p>	<p>Biodiversity risk assessments at Sanofi sites</p>	<p>SDG 15: Life on land</p> 	<p>SDG 15.5: Take urgent and significant action to reduce the degradation of natural habitats, halt the loss of biodiversity and, by 2020, protect and prevent the extinction of threatened species</p>
----------------------------	---	--	--	---	---

(a) "Any employee" includes Sanofi employees, temporary workers and subcontractors.